Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

A Closer Look at Five Stocks on the Move on Monday

Shares of MeetMe Inc (NASDAQ:MEET) have surged by nearly 13% after the company posted second quarter EPS of $0.09, beating the estimates by $0.04. Its revenue of $16.4 million surged by 48% on the year and topped analysts’ expectations by $1.13 million. The revenue growth was impacted by an 82% annual increase in mobile revenue, which also represented more than 90% of the total, while the number of mobile monthly active users went up by 32% to 4.84 million. Among the funds in our database, only eight reported stakes in the company as of the end of March, having amassed slightly over 11% of the company’s outstanding stock.

TOP SHIPS Thrives On Strong Results

TOP SHIPS Inc (NASDAQ:TOPS)’s stock has surged by nearly 160% following the company’s earnings release on Friday evening. For the first half of the year, the company posted EPS of $0.08 on revenue of $11.62 million, up by 147.2% year-over-year. For the same period last year, the firm had registered a net loss of $2.74 per share. None of the funds from our database held shares of TOP SHIPS heading into the second quarter, which is not surprising, since the company has a market cap of just $20 million (including today’s gains) and smart money investors tend to stay away from nano-cap stocks.

Follow Top Ships Inc. (NASDAQ:TOPS)
Trade (NASDAQ:TOPS) Now!

Keryx Slips On Production Interruption

Finally, there’s Keryx Biopharmaceuticals (NASDAQ:KERX), which has plummeted more than 31% on Monday. Before the market opened, the company reported a second-quarter net loss of $0.42 per share, on revenue of $9.29 million, which came in $720,000 above expectations. However, management also said it had halted production of its only drug, citing “manufacturing issues.” In relation to this announcement, the company also withdrew its full-year guidance, and said the supply of the renal medication in question should be restored by October. At the end of March, 11 funds among those we track held about 1/3 of Keryx Biopharmaceuticals (NASDAQ:KERX)’s float. Among them was Seth Klarman’s Baupost Group, which owned more than 25.79 million shares.

Follow Keryx Biopharmaceuticals Inc (NASDAQ:KERX)
Trade (NASDAQ:KERX) Now!

Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.